Associated Papers
Neoantigenic properties of TP53 variants influence cancer risk in individuals with Li-Fraumeni syndrome.
Montellier E et al.
Ebiomedicine, 2026
A quantitative, Bayesian-informed approach to gene-specific variant classification: Updated Expert Panel recommendations improve classification of TP53 germline variants for Li-Fraumeni syndrome.
Fortuno C et al.
Genome Medicine, 2025
p53 drives lung cancer regression through a TSC2/TFEB-dependent senescence program.
Wang M et al.
Cancer Discovery, 2025
TP53 variant clusters stratify phenotypic diversity in germline carriers and reveal an osteosarcoma-prone subgroup.
Fischer NW et al.
Nature Communications, 2025
p53 regulates DREAM complex-mediated repression in a p21-independent manner.
Agrawal R et al.
The Embo Journal, 2025
Clustering of TP53 variants into functional classes correlates with cancer risk and identifies different phenotypes of Li-Fraumeni syndrome.
Montellier E et al.
Iscience, 2024
Decitabine induces IRF7-mediated immune responses in p53-mutated triple-negative breast cancer: a clinical and translational study.
Wang H et al.
Frontiers of Medicine, 2024
The Competition of Yin and Yang: Exploring the Role of Wild-Type and Mutant p53 in Tumor Progression.
Cai BH et al.
Biomedicines, 2023
Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types.
Sasaki K et al.
Scientific Reports, 2023
Multifaceted role for p53 in pancreatic cancer suppression.
Mello SS et al.
Proceedings of the National Academy of Sciences of the United States of America, 2023
A role of cytoplasmic p53 in the regulation of metabolism shown by bat-mimicking p53 NLS mutant mice.
Sanford JD et al.
Cell Reports, 2023
TP53_PROF: a machine learning model to predict impact of missense mutations in TP53.
Ben-Cohen G et al.
Briefings in Bioinformatics, 2022
Immune pathways and TP53 missense mutations are associated with longer survival in canine osteosarcoma.
Das S et al.
Communications Biology, 2021
p53 mediates target gene association with nuclear speckles for amplified RNA expression.
Alexander KA et al.
Molecular Cell, 2021
α-Ketoglutarate links p53 to cell fate during tumour suppression.
Morris JP et al.
Nature, 2019
Gain-of-function mutant p53: history and speculation.
Bargonetti J et al.
Journal of Molecular Cell Biology, 2019
Finding driver mutations in cancer: Elucidating the role of background mutational processes.
Brown AL et al.
Plos Computational Biology, 2019
The Cdkn1aSUPER Mouse as a Tool to Study p53-Mediated Tumor Suppression.
Torgovnick A et al.
Cell Reports, 2018
Structural Basis for the Interaction between p53 Transactivation Domain and the Mediator Subunit MED25.
Lee MS et al.
Molecules (basel, Switzerland), 2018
Mutational processes shape the landscape of TP53 mutations in human cancer.
Giacomelli AO et al.
Nature Genetics, 2018
A p53 Super-tumor Suppressor Reveals a Tumor Suppressive p53-Ptpn14-Yap Axis in Pancreatic Cancer.
Mello SS et al.
Cancer Cell, 2017
Mutant p53 establishes targetable tumor dependency by promoting unscheduled replication.
Singh S et al.
The Journal of Clinical Investigation, 2017
An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness.
Rigolin GM et al.
Oncotarget, 2017
The Transactivation Domains of the p53 Protein.
Raj N et al.
Cold Spring Harbor Perspectives in Medicine, 2017
Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations.
Rigolin GM et al.
Journal of Hematology & Oncology, 2016
Characterization of the p300 Taz2-p53 TAD2 complex and comparison with the p300 Taz2-p53 TAD1 complex.
Miller Jenkins LM et al.
Biochemistry, 2015
Shared structural features of the 9aaTAD family in complex with CBP.
Piskacek M et al.
Molecular Biosystems, 2015
Dynamic roles of p53-mediated metabolic activities in ROS-induced stress responses.
Jiang L et al.
Cell Cycle (georgetown, Tex.), 2015
Inappropriate p53 activation during development induces features of CHARGE syndrome.
Van Nostrand JL et al.
Nature, 2014
Insights into wild-type and mutant p53 functions provided by genetically engineered mice.
Donehower LA
Human Mutation, 2014
Illuminating p53 function in cancer with genetically engineered mouse models.
Garcia PB et al.
Seminars in Cell & Developmental Biology, 2014
Guilty as CHARGED: p53's expanding role in disease.
Van Nostrand JL et al.
Cell Cycle (georgetown, Tex.), 2014
Mutant p53: one name, many proteins.
Freed-Pastor WA et al.
Genes & Development, 2012
Deconstructing p53 transcriptional networks in tumor suppression.
Bieging KT et al.
Trends in Cell Biology, 2012
Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.
Freed-Pastor WA et al.
Cell, 2012
Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression.
Brady CA et al.
Cell, 2011
Structure of the p53 transactivation domain in complex with the nuclear receptor coactivator binding domain of CREB binding protein.
Lee CW et al.
Biochemistry, 2010
Effects of stability on the biological function of p53.
Khoo KH et al.
The Journal of Biological Chemistry, 2009
Interaction between the transactivation domain of p53 and PC4 exemplifies acidic activation domains as single-stranded DNA mimics.
Rajagopalan S et al.
The Journal of Biological Chemistry, 2009
The contribution of transactivation subdomains 1 and 2 to p53-induced gene expression is heterogeneous but not subdomain-specific.
Smith JM et al.
Neoplasia (new York, N.y.), 2007
Four domains of p300 each bind tightly to a sequence spanning both transactivation subdomains of p53.
Teufel DP et al.
Proceedings of the National Academy of Sciences of the United States of America, 2007
The functional domains in p53 family proteins exhibit both common and distinct properties.
Harms KL et al.
Cell Death and Differentiation, 2006
Structural basis for gene activation by p53 family members.
Scoumanne A et al.
Cancer Biology & Therapy, 2005
The interaction of p53 with replication protein A mediates suppression of homologous recombination.
Romanova LY et al.
Oncogene, 2004
Definition of the p53 functional domains necessary for inducing apoptosis.
Zhu J et al.
The Journal of Biological Chemistry, 2000